Human Immunodeficiency Viruses (HIV) Clinical Trials Global Market Report 2025
상품코드:1855901
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
인간면역결핍 바이러스(HIV) 임상시험 시장 규모는 최근 수년간 강력하게 성장하고 있습니다. 2024년 17억 7,000만 달러에서 2025년에는 19억 4,000만 달러에 달하고, CAGR 9.3%로 확대될 전망입니다. 실적기간 내 성장은 약물 내성 HIV 균주의 확산 증가, 맞춤형 HIV 치료에 대한 수요 증가, 조기 진단 및 치료에 대한 주목 증가, 임상 연구 기관의 확대, HIV 관련 병존 질환에 대한 의식 증가에 기인하였습니다.
인간면역결핍 바이러스(HIV) 임상시험 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 연평균 복합 성장률(CAGR) 9.0%로 27억 3,000만 달러로 성장할 전망입니다. 예측기간 내 성장의 원동력은 HIV 감염의 유병률 증가, HIV 예방 및 치료에 대한 인식 증가, 항레트로바이러스 요법의 채택 확대, HIV 연구에 대한 정부 자금 및 지원 증가, 생명공학 및 제약 부문의 투자 증가입니다. 예측 기간의 주요 동향으로는 HIV 진단의 기술 주도형 혁신, 항레트로바이러스 요법(ART) 제제의 진보, 바이오마커 식별의 발전, 기술 대응 원격 모니터링 툴, 디지털 헬스 플랫폼의 통합 등이 있습니다.
인간면역결핍 바이러스의 감염 증가는 인간면역결핍 바이러스 임상시험 시장의 성장을 가속화할 것으로 예측됩니다. 인간면역결핍 바이러스 감염은 바이러스가 면역계를 공격하고 약화시킴으로써 발병하여 감염에 걸리기 쉽고 후천성 면역결핍 증후군으로 진행될 수 있습니다. HIV 감염자 증가는 주로 감염 경로에 대한 인식이 불충분하기 때문에 고위험 행동이나 검사의 지연으로 이어져, 바이러스의 확산을 조장하고 있는 것에 기인하고 있습니다. 인간면역결핍 바이러스 임상시험은 예방을 강화하고, 질병 관리를 개선하며, 감염률과 질병의 진행을 억제하기 위한 신약, 백신, 치료 접근법을 평가함으로써 이 문제를 해결하는 데 중요한 역할을 합니다. 예를 들어 미국에 본부를 둔 정부기관인 마이너리티 HIV/AIDS 기금의 2024년 8월 보고에 따르면 2023년에는 세계적으로 약 3,990만명이 HIV 보균자였으며 그 중 3,860만명이 성인이고 140만명이 소아였다고 보고했습니다. 따라서 HIV 감염의 이환율 증가는 인간면역결핍 바이러스 임상시험 시장의 확대에 기여하고 있습니다.
인간면역결핍 바이러스 임상시험 시장에서 사업을 전개하는 기업은 예방전략을 개선하고 신규 감염률을 줄이기 위해 장시간 작용형 주사치료제의 개발에 주력하고 있습니다. HIV 예방 주사는 바이러스가 체내에 정착하는 것을 억제하여 감염을 예방하기 위해 고위험군 인구에게 정기적으로 투여하는 장시간 작용제입니다. 예를 들어, 미국에 본사를 두고 있는 제약회사 길리아드 사이언시스사는 2025년 8월 HIV 치료제로서 레나카파비르로도 알려진 'Yeytuo'의 승인을 유럽연합(EU)으로부터 취득했습니다. Yeytuo는 연간 2회의 주사에 의한 예방 치료제로 임상시험에서 거의 100%의 효능을 나타내었으며, 성행위 감염을 통한 HIV-1 감염의 가능성을 대폭 감소시킵니다. 투여 스케줄을 연장함으로써, 매일 경구 노출 전 예방제와 비교하여 환자의 복약 순응과 편의성이 향상되고, 현재의 예방법에서 심각한 갭의 해결에 기여합니다. 본 치료는 고위험군 성인 및 청소년을 대상으로 하며, 종합적인 예방 틀의 일환으로 신규 HIV 감염률을 저하시키기 위한 접근을 확대하고 세계적인 대처를 지원하는 것을 목적으로 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 인간면역결핍 바이러스(HIV) 임상시험 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 성장률 분석
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 실적 : 규모와 성장(2019-2024년)
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 인간면역결핍 바이러스(HIV) 임상시험 : 총 시장 규모(TAM)
제6장 시장 세분화
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 단계별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
1상
2상
3상
4상
전임상
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 약제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
항레트로바이러스 요법(ART)
노출 전 예방제(PrEP)
노출 후 예방제(PEP)
장시간 작용형 항레트로바이러스 주사제
실험약
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 시험 디자인별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
개입 시험
관찰 시험
확장 액세스 시험
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 환자 집단별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
성인
소아
노인
임산부
고위험 집단
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 최종 사용자별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제약기업
연구기관
병원
기타 최종 사용자
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 세분화 : 1상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
최초인체시험
안전성 및 내약성 시험
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 세분화 : 2상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
용량 설정 시험
유효성 시험
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 세분화 : 3상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
피보탈 시험
유효성 비교 시험
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 세분화 : 4상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
시판 후 조사
장기 안전성 시험
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 세분화 : 전임상 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
시험관내 시험
동물시험
제7장 지역별/국가별 분석
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 인간면역결핍 바이러스(HIV) 임상시험 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
인간면역결핍 바이러스(HIV) 임상시험 시장 : 경쟁 구도
인간면역결핍 바이러스(HIV) 임상시험 시장 : 기업 프로파일
Johnson & Johnson : 개요, 제품 및 서비스, 전략 및 재무 분석
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sanofi SA : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Thermo Fisher Scientific Inc.
Amgen Inc.
Gilead Sciences Inc.
Merck & Co.
IQVIA Holdings Inc.
ICON plc
Moderna Inc.
ViiV Healthcare Limited
HOOKIPA Pharma Inc.
Excision BioTherapeutics Inc.
American Gene Technologies International Inc.
Bionor Holding AS
Aelix Therapeutics
Immuno Cure BioTech Private Limited
ImmunityBio
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
인간면역결핍 바이러스(HIV) 임상시험 시장(2029년) : 새로운 기회를 제공하는 국가
인간면역결핍 바이러스(HIV) 임상시험 시장(2029년) : 새로운 기회를 제공하는 부문
인간면역결핍 바이러스(HIV) 임상시험 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
CSM
영문 목차
영문목차
Human immunodeficiency virus (HIV) clinical trials are research studies conducted on humans to evaluate the safety, effectiveness, and potential outcomes of new drugs, therapies, vaccines, or treatment strategies for preventing, managing, or curing HIV infection. These trials follow structured phases, ranging from early safety testing to large-scale efficacy studies, and provide the clinical evidence required for regulatory approval and enhanced patient care.
The primary phases of human immunodeficiency virus (HIV) clinical trials are Phase I, Phase II, Phase III, Phase IV, and preclinical. Phase I represents the first stage of testing, conducted with a small group of healthy volunteers or patients. These trials examine drug types such as antiretroviral therapy (ART), pre-exposure prophylaxis (PrEP), post-exposure prophylaxis (PEP), long-acting injectable antiretrovirals, and experimental drugs. Study designs include interventional studies, observational studies, and expanded access studies. Targeted patient populations include adults, pediatric patients, seniors, pregnant women, and high-risk groups. End-users of the results include pharmaceutical companies, research institutions, hospitals, and related organizations.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.
The human immunodeficiency virus (HIV) clinical trials market research report is one of a series of new reports from The Business Research Company that provides human immunodeficiency virus (HIV) clinical trials market statistics, including human immunodeficiency virus (HIV) clinical trials industry global market size, regional shares, competitors with a human immunodeficiency virus (HIV) clinical trials market share, detailed human immunodeficiency virus (HIV) clinical trials market segments, market trends and opportunities, and any further data you may need to thrive in the human immunodeficiency virus (HIV) clinical trials industry. This human immunodeficiency virus (HIV) clinical trials market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The human immunodeficiency viruses (HIV) clinical trials market size has grown strongly in recent years. It will grow from $1.77 billion in 2024 to $1.94 billion in 2025 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period is attributed to the increasing prevalence of drug-resistant HIV strains, rising demand for personalized HIV care, growing focus on early diagnosis and treatment, expansion of clinical research organizations, and greater awareness of HIV-related comorbidities.
The human immunodeficiency viruses (HIV) clinical trials market size is expected to see strong growth in the next few years. It will grow to $2.73 billion in 2029 at a compound annual growth rate (CAGR) of 9.0%. The growth in the forecast period is driven by the increasing prevalence of HIV infections, rising awareness of HIV prevention and treatment, growing adoption of antiretroviral therapy, increased government funding and support for HIV research, and higher investment in biotechnology and pharmaceutical sectors. Key trends in the forecast period include technology-driven innovations in HIV diagnostics, advancements in antiretroviral therapy (ART) formulations, developments in biomarker identification, technology-enabled remote monitoring tools, and integration of digital health platforms.
The increasing number of human immunodeficiency virus infections is expected to drive the growth of the human immunodeficiency virus clinical trials market. Human immunodeficiency virus infections occur when the virus attacks and weakens the immune system, making individuals more vulnerable to infections and potentially progressing to acquired immunodeficiency syndrome. The rise in HIV cases is primarily attributed to insufficient awareness regarding transmission methods, which leads to high-risk behaviors and delays in testing, thereby facilitating the spread of the virus. Human immunodeficiency virus clinical trials play a vital role in addressing this issue by evaluating new drugs, vaccines, and treatment approaches to enhance prevention, improve disease management, and reduce transmission rates and disease progression. For example, in August 2024, the Minority HIV/AIDS Fund, a government agency based in the United States, reported that in 2023, an estimated 39.9 million people globally were living with HIV, including 38.6 million adults and 1.4 million children, reflecting an increase compared to previous years. Therefore, the growing incidence of HIV infections is contributing to the expansion of the human immunodeficiency virus clinical trials market.
Companies operating in the human immunodeficiency virus clinical trials market are focusing on developing long-acting injectable treatments to improve prevention strategies and reduce the rate of new infections. An HIV prevention injection is a long-acting medication administered at regular intervals to high-risk individuals to prevent infection by inhibiting the virus from establishing itself in the body. For example, in August 2025, Gilead Sciences Inc., a pharmaceutical company based in the United States, received approval from the European Union for Yeytuo, also known as lenacapavir, for the treatment of HIV. Yeytuo is a twice-yearly injectable prevention treatment that has shown nearly one hundred percent efficacy in clinical trials, significantly reducing the likelihood of acquiring HIV-1 through sexual transmission. The extended dosing schedule improves patient adherence and convenience when compared to daily oral pre-exposure prophylaxis, helping to address a significant gap in current prevention methods. This treatment is intended for adults and adolescents at increased risk, with the goal of expanding access and supporting global efforts to lower new HIV infection rates as part of a comprehensive prevention framework.
In July 2025, Elliott Investment Management L.P., an investment company based in the United States, along with Patient Square Capital LP and Veritas Capital Fund Management L.L.C., both health-focused investment firms based in the United States, completed the acquisition of Syneos Health for seven point one billion United States dollars. Through this acquisition, the investment firms aim to accelerate the growth of Syneos Health, improve customer service, and transform the organization into a technology-driven leader in biopharmaceutical solutions. Syneos Health is a pharmaceutical company based in the United States that conducts human immunodeficiency virus clinical trials.
Major players in the human immunodeficiency viruses (HIV) clinical trials market are Johnson & Johnson, F. Hoffmann-La Roche Ltd., Pfizer Inc., AbbVie Inc., Sanofi S.A., Thermo Fisher Scientific Inc., Amgen Inc., Gilead Sciences Inc., Merck & Co., IQVIA Holdings Inc., ICON plc, Moderna Inc., ViiV Healthcare Limited, HOOKIPA Pharma Inc., Excision BioTherapeutics Inc., American Gene Technologies International Inc., Bionor Holding AS, Aelix Therapeutics, Immuno Cure BioTech Private Limited, ImmunityBio.
North America was the largest region in the human immunodeficiency viruses (HIV) clinical trials market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human immunodeficiency virus (HIV) clinical trials report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the human immunodeficiency virus (HIV) clinical trials market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The human immunodeficiency virus (HIV) clinical trials market includes revenues earned by entities by providing services such as clinical study design and protocol development, patient recruitment and screening, and medical monitoring and care. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Human Immunodeficiency Viruses (HIV) Clinical Trials Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on human immunodeficiency viruses (hiv) clinical trials market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for human immunodeficiency viruses (hiv) clinical trials ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The human immunodeficiency viruses (hiv) clinical trials market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Characteristics
3. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Trends And Strategies
4. Human Immunodeficiency Viruses (HIV) Clinical Trials Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Growth Analysis And Strategic Analysis Framework
5.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Growth Rate Analysis
5.4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Total Addressable Market (TAM)
6. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Segmentation
6.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Phase I
Phase II
Phase III
Phase IV
Preclinical
6.2. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Antiretroviral Therapy (ART)
Pre-Exposure Prophylaxis (PrEP)
Post-Exposure Prophylaxis (PEP)
Long-Acting Injectable Antiretrovirals
Experimental Drugs
6.3. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Interventional Studies
Observational Studies
Expanded Access Studies
6.4. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adults
Pediatric Patients
Seniors
Pregnant Women
High-Risk Populations
6.5. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pharmaceutical Companies
Research Institutes
Hospitals
Other End-Users
6.6. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase I, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-In-Human Studies
Safety And Tolerability Studies
6.7. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase Ii, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Dose-Finding Studies
Efficacy Studies
6.8. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase Iii, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pivotal Trials
Comparative Efficacy Studies
6.9. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Phase Iv, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Post-Marketing Surveillance
Long-Term Safety Studies
6.10. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Sub-Segmentation Of Preclinical, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
In Vitro Studies
Animal Studies
7. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Regional And Country Analysis
7.1. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market
8.1. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market
9.1. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
9.2. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market
10.1. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market
11.1. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
11.2. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market
12.1. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market
13.1. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market
14.1. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
14.2. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market
15.1. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
15.2. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market
16.1. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market
17.1. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market
18.1. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market
19.1. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market
20.1. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market
21.1. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
21.2. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market
22.1. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market
23.1. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
23.2. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market
24.1. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
24.2. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market
25.1. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
25.2. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market
26.1. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
26.2. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market
27.1. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market
28.1. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
28.2. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market
29.1. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market Overview
29.2. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Phase, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Human Immunodeficiency Viruses (HIV) Clinical Trials Market, Segmentation By Study Design, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Landscape And Company Profiles
30.1. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Landscape
30.2. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Company Profiles
30.2.1. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
31. Human Immunodeficiency Viruses (HIV) Clinical Trials Market Other Major And Innovative Companies
31.1. Thermo Fisher Scientific Inc.
31.2. Amgen Inc.
31.3. Gilead Sciences Inc.
31.4. Merck & Co.
31.5. IQVIA Holdings Inc.
31.6. ICON plc
31.7. Moderna Inc.
31.8. ViiV Healthcare Limited
31.9. HOOKIPA Pharma Inc.
31.10. Excision BioTherapeutics Inc.
31.11. American Gene Technologies International Inc.
31.12. Bionor Holding AS
31.13. Aelix Therapeutics
31.14. Immuno Cure BioTech Private Limited
31.15. ImmunityBio
32. Global Human Immunodeficiency Viruses (HIV) Clinical Trials Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market
34. Recent Developments In The Human Immunodeficiency Viruses (HIV) Clinical Trials Market
35. Human Immunodeficiency Viruses (HIV) Clinical Trials Market High Potential Countries, Segments and Strategies
35.1 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2029 - Countries Offering Most New Opportunities
35.2 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2029 - Segments Offering Most New Opportunities
35.3 Human Immunodeficiency Viruses (HIV) Clinical Trials Market In 2029 - Growth Strategies
